126 related articles for article (PubMed ID: 31626700)
1. Hypoxia-Induced TGFBI as a Serum Biomarker for Laboratory Diagnosis and Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
Yang L; Cui R; Li Y; Liang K; Ni M; Gu Y
Lab Med; 2020 Jul; 51(4):352-361. PubMed ID: 31626700
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta-induced, an extracellular matrix interacting protein, enhances glycolysis and promotes pancreatic cancer cell migration.
Costanza B; Rademaker G; Tiamiou A; De Tullio P; Leenders J; Blomme A; Bellier J; Bianchi E; Turtoi A; Delvenne P; Bellahcène A; Peulen O; Castronovo V
Int J Cancer; 2019 Sep; 145(6):1570-1584. PubMed ID: 30834519
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of transforming growth factor beta-induced in circulating tumor cell subline from pancreatic cancer cell line.
Sato T; Muramatsu T; Tanabe M; Inazawa J
Cancer Sci; 2018 Nov; 109(11):3623-3633. PubMed ID: 30156359
[TBL] [Abstract][Full Text] [Related]
4. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
5. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288
[TBL] [Abstract][Full Text] [Related]
6. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Byrling J; Hilmersson KS; Ansari D; Andersson R; Andersson B
Clin Transl Oncol; 2022 Feb; 24(2):297-304. PubMed ID: 34319497
[TBL] [Abstract][Full Text] [Related]
8. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
9. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
Kendrick ZW; Firpo MA; Repko RC; Scaife CL; Adler DG; Boucher KM; Mulvihill SJ
HPB (Oxford); 2014 Jul; 16(7):670-6. PubMed ID: 24308545
[TBL] [Abstract][Full Text] [Related]
10. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
11. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
[TBL] [Abstract][Full Text] [Related]
13. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.
Balasenthil S; Chen N; Lott ST; Chen J; Carter J; Grizzle WE; Frazier ML; Sen S; Killary AM
Cancer Prev Res (Phila); 2011 Jan; 4(1):137-49. PubMed ID: 21071578
[TBL] [Abstract][Full Text] [Related]
14. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.
Lin C; Wu WC; Zhao GC; Wang DS; Lou WH; Jin DY
Medicine (Baltimore); 2016 Aug; 95(31):e4527. PubMed ID: 27495108
[TBL] [Abstract][Full Text] [Related]
15. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
[TBL] [Abstract][Full Text] [Related]
16. Survivin expression and serum levels in pancreatic cancer.
Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
[TBL] [Abstract][Full Text] [Related]
17. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.
Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM
Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932
[TBL] [Abstract][Full Text] [Related]
18. Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer.
Satoh M; Takano S; Sogawa K; Noda K; Yoshitomi H; Ishibashi M; Mogushi K; Takizawa H; Otsuka M; Shimizu H; Miyazaki M; Nomura F
Cancer Sci; 2017 Apr; 108(4):795-803. PubMed ID: 28161904
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.
Wang X; Ren H; Zhao T; Ma W; Dong J; Zhang S; Xin W; Yang S; Jia L; Hao J
Oncotarget; 2016 Mar; 7(12):13717-29. PubMed ID: 26872370
[TBL] [Abstract][Full Text] [Related]
20. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
